| Literature DB >> 29335625 |
Stefan O Ciurea1, Kai Cao2, Marcelo Fernandez-Vina3, Piyanuch Kongtim4, Monzr Al Malki5, Ephraim Fuchs6, Leo Luznik6, Xiao-Jun Huang7, Fabio Ciceri8, Franco Locatelli9, Franco Aversa10, Luca Castagna11, Andrea Bacigalupo12, Massimo Martelli13, Didier Blaise14, Rupert Handgretinger15, Denis-Claude Roy16, Paul O'Donnell17, Asad Bashey18, Hillard M Lazarus19, Karen Ballen20, Bipin N Savani21, Mohamad Mohty22, Arnon Nagler23,24.
Abstract
Haploidentical donors are now increasingly considered for transplantation in the absence of HLA-matched donors or when an urgent transplant is needed. Donor-specific anti-HLA antibodies (DSA) have been recently recognized as an important barrier against successful engraftment of donor cells, which can affect transplant survival. DSA appear more prevalent in this type of transplant due to higher likelihood of alloimmunization of multiparous females against offspring's HLA antigens, and the degree of mismatch. Here we summarize the evidence for the role of DSA in the development of primary graft failure in haploidentical transplantation and provide consensus recommendations from the European Society for Blood and Marrow Transplant Group on testing, monitoring, and treatment of patients with DSA receiving haploidentical hematopoietic progenitor cell transplantation.Entities:
Mesh：
Substances：
Year: 2018 PMID： 29335625 PMCID： PMC7232774 DOI： 10.1038/s41409-017-0062-8
Source DB: PubMed Journal: Bone Marrow Transplant ISSN： 0268-3369 Impact factor: 5.483